[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Janssen-Cilag Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,60,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100633864","a-study-of-guselkumab-treatment-persistence-in-psoriatic-arthritis-participants-100633864",false,"NCT07532226","A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants","A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients","PEGASUS","Inclusion criteria:\n\n* Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)\n* Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study\n* Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication\n* The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations\n* Must have received the information note, given his\u002Fher oral agreement and has not objected to the collection of his\u002Fher data in accordance with French requirements\n\nExclusion Criteria:\n\n* Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.\n* Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase \\[JAK\\] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA\u002FPsO at the same time\n* Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)\n* Unwilling or unable to participate in long-term data collection\n* Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)\n* Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study\n* Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).",[25],"Arthritis, Psoriatic","RECRUITING","2026-06-04",{"date":29,"type":30},"2026-06-05","ACTUAL",{"date":32,"type":30},"2026-04-17",{"date":34,"type":21},"2029-12-10",{"name":36,"class":37},"Janssen-Cilag Ltd.","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":38},"100611566","a-study-to-observe-real-world-evidence-of-guselkumab-treatment-in-participants-with-ulcerative-colitis-and-crohns-disease-in-the-united-kingdom-uk-100611566","NCT07242248","A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)","Real World Observation of Guselkumab Treatment in Patients With Ulcerative Colitis and Crohn's Disease - a Study of Treatment Outcomes in the UK","GUSTO-UK","Inclusion Criteria:\n\n* Must be eligible for biologic treatment and initiate guselkumab according to the approved indications as described in the current version of the summary of product characteristics (SmPC) of the drug. Decision to prescribe must solely be made by the treating physician in line with the Trust's\u002F Health Board's treatment guidance. Enrolment must take place before or at the day of first administration (but after treatment decision by physician)\n* Must have a confirmed diagnosis of moderate-to-severe Crohn's Disease (CD) or Ulcerative Colitis (UC) recorded in their medical records\n* Must sign a informed consent form (ICF) allowing source data verification in accordance with local requirements\n\nExclusion Criteria:\n\n* Contraindicated to guselkumab per the label\n* Is currently enrolled in an interventional clinical study\n* Has been previously exposed to interleukin (IL)-23 inhibitors, including Tremfya® (guselkumab), Skyrizi ® (risankizumab) and Omvoh® (mirikizumab). As an exception, participants with history of ustekinumab exposure, may be included\n* Has a history of more than 4 lines of advanced inflammatory bowel disease (IBD) therapy (biologics and \u002For small molecules)\n* Is unable to provide informed consent",{"count":48,"type":21},220,"The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult participants with moderately to severely active Ulcerative Colitis (UC) or Crohn's Disease (CD) under real-world settings. CD and UC are the main type of Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.",[51,52,53],"Inflammatory Bowel Disease","Colitis, Ulcerative","Crohn's Disease",{"date":29,"type":30},{"date":56,"type":30},"2025-11-17",{"date":58,"type":21},"2029-03-17",{"name":36,"class":37},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100538014","a-study-of-clinical-outcomes-in-patients-with-relapsedrefractory-multiple-myeloma-rrmm-treated-with-t-cell-redirectors-outside-of-clinical-trials-100538014","NCT06285318","A Study of Clinical Outcomes in Patients With Relapsed\u002FRefractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials","A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed\u002FRefractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials","REALiTEC\u002FTAL","Inclusion Criteria:\n\n* Have a documented diagnosis of multiple myeloma\n* Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \\& talquetamab can be included in both REALiTEC and REALiTAL cohorts\n* Received at least one dose of teclistamab\u002Ftalquetamab\n* Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country\u002Fsite-specific requirements\n\nExclusion Criteria:\n\n* To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial\n* To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial\n* Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3",{"count":69,"type":21},900,"The purpose of this study is to describe the use of teclistamab\u002Ftalquetamab in the treatment of patients with RRMM outside of clinical trials.",[72],"Relapsed\u002FRefractory Multiple Myeloma (RRMM)",{"date":29,"type":30},{"date":75,"type":30},"2023-12-18",{"date":77,"type":21},"2026-09-24",{"name":36,"class":37},68,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":38},"100627484","a-study-of-guselkumab-after-switching-from-ustekinumab-in-participants-with-moderate-to-severe-psoriasis-100627484","NCT07449234","A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis","A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine","G-LINK","Inclusion criteria:\n\n* Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment\n* Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab\n* Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab\n* Participants must understand and be willing and able to answer patient-reported outcomes (PROs)\n* Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements\n\nExclusion criteria:\n\n* Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution\u002Fliquid\n* Pregnancy or breastfeeding\n* Currently enrolled in an interventional study\n* Currently enrolled in an observational study sponsored or managed by a Janssen company",{"count":20,"type":21},"The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.",[91],"Psoriasis","2026-05-07",{"date":94,"type":30},"2026-05-08",{"date":96,"type":30},"2026-02-09",{"date":98,"type":21},"2027-09-01",{"name":36,"class":37},""]